Leclaza / Lazcluze in Qatar

Leclaza / Lazcluze - overview

Leclaza / Lazcluze (lazertinib) is manufactured by Yuhan / J&J and indicated for EGFR+ 1L NSCLC (combo w/ amivantamab). It is a approved by the US FDA in 2024 and may be accessible to patients in Qatar through a Named Patient Program or personal-import pathway.

Access in Qatar

Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.

How Reserve Meds coordinates access in Qatar

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Qatar-specific eligibility.
3. Treating physician in Qatar issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Leclaza / Lazcluze from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Qatar.

Typical timeline for Qatar

End-to-end, most requests are completed in 2-6 weeks. Qatar's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Qatar ask

• Is the pathway legal in Qatar? Yes - it operates under Qatar's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Qatar able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Leclaza / Lazcluze in Qatar

Request Leclaza / Lazcluze